ReNerve has locked in a flexible A$5 million convertible note facility with RiverFort, drawing an initial A$1.6 million to back its commercial push and US sales ramp-up.
- Up to A$5 million convertible note facility over three years
- Initial A$1.6 million drawdown nets approximately A$1.36 million
- Facility supports US market expansion and product portfolio growth
- Convertible securities capped to limit dilution on first drawdown
- Repayment via cash or share conversion with investor protections
Flexible Funding to Accelerate Commercialisation
ReNerve Limited (ASX:RNV) has secured a convertible note funding facility worth up to A$5 million with RiverFort Global Opportunities PCC Ltd. The staged facility, available over three years, offers the company flexible capital access aligned with its commercial milestones. An initial drawdown of about A$1.6 million has already been made, providing around A$1.36 million in net cash after fees and discounts to support immediate operational needs.
CEO Dr Julian Chick emphasised that the facility's structure allows ReNerve to manage dilution and cash flow prudently while advancing its strategic goals. The funding is earmarked for expanding the product portfolio, boosting US sales and distribution, and broader market development initiatives. This aligns with ReNerve's recent momentum in building its presence and product traction in key international markets.
Convertible Notes with Defined Terms and Investor Safeguards
The convertible securities issued under the facility carry a face value of A$1 each and were initially issued at a 10% discount. The first tranche's maximum dilution is capped at just over 16 million shares, with options issued subject to shareholder approval at the next general meeting. Each drawdown matures 18 months after issuance, with repayments commencing six months post-drawdown through monthly instalments payable in cash or shares.
Conversion prices are set at a 30% premium to the five-day VWAP at drawdown, with the first tranche fixed at 10.0849 cents. Should cash repayments be missed, the investor gains additional conversion rights at a 10% discount to the VWAP. A drawdown fee applies, varying between 4% and 5%, depending on the repayment method chosen by the company.
The facility also includes standard investor protections restricting further secured debt and equity-linked financings without consent, alongside customary default provisions. Notably, proceeds from ReNerve’s R&D Tax Incentive may be directed towards repaying the facility, reflecting a secured interest over the company’s assets and future tax incentives.
Backing a Growing Medtech Innovator in Nerve Repair
ReNerve is riding a wave of growth in the peripheral nerve repair market, which is projected to expand from US$1.6 billion in 2024 to over US$6 billion by 2031. Its flagship product, the FDA-cleared NervAlign® Nerve Cuff, has demonstrated significant clinical benefits, notably slashing post-surgical pain scores from 7.1 to 0.4 in treated patients versus 3.3 in standard care.
The company’s portfolio also includes Empliq™ tissue products and next-generation nerve repair devices in development, such as the NervAlign® Nerve Conduit Range and Bionic Nerve technology. ReNerve’s FY25 revenue surged 53% to $271,000, with further gains in FY26, underscoring commercial traction. The new funding facility is poised to underpin ongoing sales growth and product launches, including expanding its footprint in the US and Asia-Pacific markets.
ReNerve’s recent regulatory wins and distribution deals in Indonesia and Malaysia complement this capital raise, providing a multi-pronged approach to scaling its innovative nerve repair solutions in high-potential regions. The staged nature of the facility offers capital flexibility as the company navigates these complex market expansions and regulatory pathways.
Bottom Line?
ReNerve’s new convertible note facility equips it with a flexible financial runway to capitalise on growing market demand and accelerate product commercialisation, but future dilution and drawdowns hinge on shareholder approvals and market conditions.
Questions in the middle?
- How will ReNerve balance future drawdowns with shareholder dilution concerns?
- What milestones will trigger subsequent funding tranches over the three-year period?
- How quickly can ReNerve translate this funding into sustained US sales growth?